Quadrant Capital Group LLC Macrogenics Inc Transaction History

Quadrant Capital Group LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$4.82 - $7.24 $954 - $1,433	-198 Reduced 71.48%	79 $0
Q4 2022 Feb 10, 2023	BUY	$3.34 - $6.98 $925 - $1,933	277 New	277 $1,000
Q2 2022 Aug 09, 2022	SELL	$2.25 - $9.99 $65 - $289	-29 Closed	0 $0
Q1 2022 May 06, 2022	BUY	$8.12 - $16.9 $235 - $490	29 New	29 $0
Q3 2019 Oct 24, 2019	SELL	$12.44 - $17.48 $49,200 - $69,133	-3,955 Closed	0 $0
Q2 2019 Jul 24, 2019	BUY	$14.51 - $19.71 $57,387 - $77,953	3,955 New	3,955 $66,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

Stay updated on Quadrant Capital Group LLC with notifications on news.